Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more) Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Kineta Inc KA

Healthcare Biotechnology
Kineta, Inc. is a clinical-stage biotechnology company. The Company has leveraged its expertise in innate immunity and is focused on discovering and developing potentially differentiated immunotherapies that address the mechanisms of cancer immune resistance: immunosuppression, exhausted T cells and poor tumor immunogenicity. Its pipeline of immunotherapies includes KVA12123, which is a... see more

Recent & Breaking News (NDAQ:KA)

Analysts Are Bullish On These 5 Stocks That Went Public This Year

Benzinga.com  August 13, 2016

Proteostasis Therapeutics Issues Mid-Year Corporate Update on Cystic Fibrosis Pipeline Programs

GlobeNewswire August 11, 2016

Proteostasis Therapeutics Achieves Preclinical Milestone in Astellas Pharma Collaboration

GlobeNewswire August 8, 2016

Proteostasis Therapeutics Announces Key Leadership Appointments

GlobeNewswire August 8, 2016

Proteostasis Therapeutics, Inc. Presents New Data Demonstrating Potential for Genotype-Agnostic and Combination Therapies for People with Cystic Fibrosis

GlobeNewswire March 30, 2016

Proteostasis Therapeutics, Inc. Announces Scientific Presentations at 13th Annual European Cystic Fibrosis Society Basic Science Conference

GlobeNewswire March 28, 2016

Proteostasis Therapeutics, Inc. Announces Closing of Initial Public Offering

GlobeNewswire February 18, 2016

Proteostasis Therapeutics Inc. (Nasdaq: PTI) to Ring the Nasdaq Stock Market Opening Bell in Celebration of IPO

GlobeNewswire February 11, 2016

Proteostasis Therapeutics, Inc. Announces Pricing of Initial Public Offering

GlobeNewswire February 11, 2016